• Angiotensin II Workflows for Cardiac Remodeling

  2026-09-25

  Use Angiotensin II to connect receptor-driven signaling with practical cell and animal models of vascular and cardiac remodeling. This guide pairs product-based dosing benchmarks with a macrophage-focused heart-failure study, while separating reported findings from workflow recommendations.

• N-MYC–eIF4G1 Signaling Sustains inv(16) AML

  2026-09-25

  Peramangalam et al. identify N-MYC as a survival regulator in inv(16) acute myeloid leukemia and connect its activity to the previously unrecognized AML effector eIF4G1. Their findings link CBFβ-SMMHC inhibition with reduced MYCN expression and support further investigation of the N-MYC/eIF4G1 axis in leukemia models.

• Oxaliplatin: From DNA Damage to Translational Strategy

  2026-09-24

  Oxaliplatin is more than a cytotoxic benchmark: its DNA-damaging activity offers researchers a way to interrogate apoptosis, drug response and the limits of biomarker transfer. This article connects its mechanism and practical use with evidence from a bladder cancer CRISPR screen, highlighting why platinum agents should be evaluated individually in translational studies.

• Irinotecan Workflows for Cancer and Toxicity Models

  2026-09-24

  Use Irinotecan (CPT-11) to build interpretable topoisomerase I response experiments in colorectal cancer models, then extend the workflow to chemotherapy-associated gut–liver injury questions. Practical dosing, controls, and troubleshooting help distinguish compound handling problems from real biological variation.

• GSK 2837808A: A Selective LDHA Inhibitor

  2026-09-23

  GSK 2837808A is a potent lactate dehydrogenase A inhibitor reported to reduce glucose consumption and reverse aerobic glycolysis in cancer-cell experiments. Its established product evidence includes LDHA/LDHB potency and pharmacokinetic limitations; its use to test the NAT1–ENO1–lactate–PD-L1 pathway in colorectal cancer remains exploratory.

• Biomimetic Microparticles Disrupt Tumor pH Balance

  2026-09-23

  The reference study presents tumor cell-derived microparticles that co-deliver syrosingopine and a pH-activated doxorubicin prodrug to disrupt both intracellular and extracellular tumor pH homeostasis. By coupling lactate-export blockade with immunogenic chemotherapy and immune remodeling, the platform offers a mechanistically integrated approach to chemo-immunotherapy.

• HyperPFU™ high-fidelity DNA polymerase Guide

  2026-09-22

  HyperPFU™ high-fidelity DNA polymerase is intended for accurate amplification of long, GC-rich, inhibitor-containing, or otherwise difficult DNA templates. It is appropriate for blunt-ended products used in cloning and sequencing, but not for workflows that require 3′-A overhangs or predefined sticky ends.

• EZ Cap™ Cas9 mRNA for Functional Gene Studies

  2026-09-22

  Use transient Cas9 expression to test gene function without committing to a DNA-based expression system. This guide connects EZ Cap™ Cas9 mRNA (5-moUTP) with zebrafish neurodegeneration workflows, neural-cell assays, and practical troubleshooting for CRISPR-Cas9 genome editing.

• Patient-Derived Gastric Cancer Assembloids

  2026-09-21

  Shapira-Netanelov and colleagues developed a patient-derived gastric cancer assembloid system that combines matched tumor organoids with stromal cell subpopulations from the same tumor. The model reproduced clinically relevant tumor–stroma interactions and showed that stromal composition can alter gene expression and drug sensitivity, supporting more physiologically informed personalized therapy studies.

• Angiotensin II in AAA Model Workflows

  2026-09-21

  Use Angiotensin II as a controlled receptor stimulus for vascular smooth muscle cell hypertrophy research, oxidative-stress assays, and vascular remodeling models. This workflow also shows how Angiotensin II challenge systems can complement targeted nanomedicine studies of abdominal aortic aneurysm biology.

• Angiotensin II: Practical Protocol and QC Guide

  2026-09-20

  This guide provides practical handling, dosing, and quality-control steps for Angiotensin II (SKU A1042) in cell and animal research workflows. It is intended for controlled receptor-stimulation experiments, vascular biology, and modeling studies, not for diagnosis, treatment, or direct clinical application.

• Angiotensin II (A1042): Practical Protocol Guide

  2026-09-19

  Angiotensin II (SKU A1042) provides a defined peptide agonist for controlled receptor-stimulation experiments, including cell signaling, vascular smooth muscle cell hypertrophy research, and vascular remodeling models. This guide covers preparation, dosing, controls, and QC; it should not be used to infer clinical efficacy or replace an approved animal or medical protocol.

• SAG for Hedgehog Pathway Activation and Modeling

  2026-09-18

  SAG is a direct Smoothened receptor agonist for controlled Hedgehog pathway activation in cell assays, neural repair models, and developmental biology. Its value is greatest when receptor-level stimulation is paired with quantitative Gli1, Ptch1, proliferation, morphology, and mitochondrial readouts.

• HyperPFU™ High-Fidelity DNA Polymerase Guide

  2026-09-18

  HyperPFU™ high-fidelity DNA polymerase is intended for accurate amplification of long, GC-rich, inhibited, or otherwise difficult DNA templates. It is useful for blunt-ended cloning and sequencing workflows, but it is not the right choice when PCR products must carry 3′-A overhangs or predefined sticky ends.

• LY2228820: A Practical p38 MAP Kinase Inhibitor Workflow

  2026-09-17

  LY2228820 enables controlled interrogation of p38α/β signaling across biochemical, cellular, cytokine, and tumor-model workflows. Its value is greatest when direct kinase inhibition is paired with phospho-MK2, cytokine, viability, and apoptosis assay readouts.

7995 records 1/533 page Next 12345 下5页 Last page